Does Canadian Public Insurance Cover MOUD? Meds, Provinces, Gaps

Canadian public insurance does cover medications for opioid use disorder, but what you pay and what paperwork you face depends on the province or territory you live in and the plan you qualify for. Every province and territory provides some public coverage for the two first-line treatments, methadone and buprenorphine/naloxone. British Columbia covers all major MOUD at 100% with no enrollment required, while other provinces attach conditions ranging from income-based cost-sharing to special authorization for newer formulations like the Sublocade injection.

Which Medications Are Covered

Canada’s national clinical guidelines, updated in November 2024 by the Canadian Research Initiative in Substance Matters, recommend buprenorphine and methadone as first-line treatments for opioid use disorder.1PubMed. Management of Opioid Use Disorder: 2024 Update to the National Clinical Practice Guideline Slow-release oral morphine, sold as Kadian, is the recommended second-line option when the first two are ineffective or not tolerated.2CRISM. National Opioid Use Disorder Guideline Oral naltrexone is rarely used because it requires a lengthy period of complete opioid abstinence before starting.

Longer-acting options have become more important in recent years. Sublocade is an extended-release buprenorphine injection given monthly. Probuphine is a buprenorphine implant for patients already stabilized on a low sublingual dose. Injectable opioid agonist treatment using hydromorphone or pharmaceutical-grade diacetylmorphine is recommended for severe, treatment-resistant cases, though program access is limited.3CADTH. Opioid Substitution Treatment Rapid Review

One boundary worth flagging if you have read about U.S. treatment: Vivitrol, the extended-release injectable naltrexone widely used south of the border, is not marketed in Canada and is not covered by any public plan. It is available only through Health Canada’s Special Access Programme or for research.4CDA-AMC. Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder

Where You Live Changes What You Pay

British Columbia

BC has the most accessible public coverage in the country. Since June 2023, all opioid agonist treatment medications are covered at 100% under PharmaCare Plan Z, open to any resident with active Medical Services Plan enrollment.5BC Gov News. BC PharmaCare Opioid Agonist Treatment Coverage There are no forms, no income verification, and no separate drug plan to sign up for. You present your prescription and personal health number at any pharmacy.6HBT. Mental Health Benefits and Resources

Automatically covered medications include methadone (Methadose and Metadol-D), generic buprenorphine/naloxone tablets, slow-release oral morphine, and the Sublocade injection. Brand-name Suboxone tablets are covered up to the generic price. Compounded methadone, high-dose buprenorphine/naloxone tablets, and certain brand-name versions require a prescriber to submit a Special Authority request.7Government of British Columbia. Drug Coverage – Opioid Use Disorder8Government of British Columbia. OAT PINs and DINs

Alberta

Alberta runs an OAT Gap Coverage Program designed to provide immediate, no-cost access to methadone, buprenorphine/naloxone, and injectable extended-release buprenorphine for anyone without existing health benefits.9Government of Alberta. Opioid Agonist Therapy Gap Coverage Program It covers up to 120 days of therapy (up to 1,500 mL of methadone or 360 tablets of buprenorphine/naloxone), during which you are expected to enroll in a permanent plan such as Non-Group Coverage or Coverage for Seniors.10Alberta Blue Cross. OAT Gap Coverage Program – Pharmacy Benefact Extensions are available if your long-term application is still pending. In practice, no one in Alberta should face a first-dose barrier, but you do need to make the transition to longer-term coverage within a few months.

Ontario

Ontario covers MOUD through two streams. Physician visits related to addiction treatment, including assessments and ongoing management, are fully covered by the Ontario Health Insurance Plan.11Arrow Medical. OHIP and Addiction Treatment The medications themselves run through the Ontario Drug Benefit program, which is available to people on Ontario Works or ODSP, seniors over 65, long-term care residents, and people enrolled in the Trillium Drug Program for high prescription costs relative to income.

Under ODB, generic buprenorphine/naloxone sublingual tablets are a general benefit. Sublocade is a Limited Use drug, so a prescriber must confirm you meet certain clinical criteria.12META:PHI. Guide to Depot Buprenorphine Methadone is covered, with pharmacies able to claim separate reimbursement for individual take-home doses.13Ontario Pharmacists Association. Opioid Agonist Therapy Slow-release oral morphine and medications used in prescribed safer supply programs are also covered through ODB.14PMC. Safer Opioid Supply in Ontario

Working-age Ontarians who are not on social assistance and have no private insurance can use the Trillium Drug Program as a safety net, but it requires enrollment and income verification, and real out-of-pocket costs can arise in that gap. Ontario also lacks public coverage for high-dose injectable hydromorphone, so injectable opioid agonist treatment programs remain rare in the province.15PMC. Prescribed Safer Supply Programs in Canada

Quebec

Quebec requires every resident to have prescription drug coverage, either through a private plan or through the public plan administered by the Régie de l’assurance maladie du Québec. The public formulary lists multiple buprenorphine/naloxone products, including generics from Pharmascience and Teva and brand-name Suboxone tablets and films. Sublocade is listed as an “exceptional medication,” meaning a prescriber or pharmacist must obtain authorization before it will be covered.16RAMQ. Buprenorphine Coverage Lookup

Quebec’s plan involves cost-sharing. For 2025–2026, patients pay a monthly deductible of $22 plus 30% co-insurance on the remaining cost, up to a monthly maximum. Children under 18, some students, and people on social assistance are exempt.17RAMQ. Amount to Pay for Prescription Drugs Enrollees also pay an annual premium of up to $766 through their income tax return, though low-income filers may owe nothing.18RAMQ. Annual Premium

Saskatchewan, Manitoba, Nova Scotia, and New Brunswick

A 2023 analysis by CADTH recorded the formulary status of MOUD across these four provinces as of May 2023.19CDA-AMC. OAT Utilization Analysis The pattern is similar across the group: methadone and sublingual buprenorphine/naloxone are available without administrative hurdles, while newer formulations usually require extra paperwork.

  • Saskatchewan: methadone and buprenorphine/naloxone are open benefits; Sublocade and Probuphine carry exception drug status.
  • Manitoba: methadone and buprenorphine/naloxone are Part 1 benefits (generally unrestricted); Sublocade and Probuphine are Part 2 benefits requiring additional criteria.
  • Nova Scotia: methadone, buprenorphine/naloxone, and Sublocade are all open benefits; only Probuphine requires exception approval.
  • New Brunswick: methadone, buprenorphine/naloxone, and Sublocade are open benefits; Probuphine requires special authorization.

Coverage for First Nations and Inuit

If you are a registered First Nations person or a recognized Inuk, your drug coverage runs through the Non-Insured Health Benefits program administered by Indigenous Services Canada, regardless of which province you live in. NIHB covers methadone, buprenorphine/naloxone (Suboxone and generics), Sublocade, and slow-release oral morphine when methadone and buprenorphine are unavailable or inappropriate.20Indigenous Services Canada. NIHB Opioid Use Disorder Treatment Policy Injectable opioid agonist treatment is also covered, as is naloxone in both injectable and nasal spray forms.21Indigenous Services Canada. NIHB Program – Opioid Use Disorder Coverage

Eligible clients pay no deductibles or co-payments. MOUD treatments are exempt from the standard 30-day maximum dispense policy that applies to other opioids. The program also covers medical transportation to access supervised treatment, reviewed every six months, and up to 22 hours of professional mental health counseling every 12 months, with additional hours available as needed. NIHB has moved many medications to open benefit status and updates its Drug Benefit List daily.22Indigenous Services Canada. NIHB Drug Benefit List Updates

If You Fall Through the Cracks

Public coverage looks broad on paper, but working-age adults can still find themselves without a plan. People who earn too much for social assistance but lack employer drug benefits are the group most likely to pay full price for a prescription. A 2017 analysis found roughly one-third of working Canadians had no employer-provided prescription drug coverage, with the lowest rates concentrated among part-time workers and those earning under $20,000 per year.23Innovative Medicines Canada. Understanding the Gap24Wellesley Institute. Prescription Drugs Health Equity Impact Assessment Alberta’s gap coverage program and BC’s universal Plan Z were designed to close that hole for MOUD specifically, but not every province has done the same.

Geography compounds the problem. A systematic review of opioid agonist therapy in rural and remote communities found that distance to clinics and pharmacies, shortages of healthcare professionals, and limited pharmacy hours all undermine access. Rural pharmacies may not regularly stock buprenorphine/naloxone, and daily witnessed dosing is demanding on pharmacy staff.25PMC. Opioid Agonist Therapy in Rural and Remote Canadian Communities

One national safety net worth knowing about, and its limits: the federal Pharmacare Act (Bill C-64) received Royal Assent in October 2024, but its first phase covers only contraception and diabetes medications. MOUD is not included. The legislation does call for a national essential drugs list, which could expand in future phases.26Government of Canada. Government of Canada Passes Legislation for National Universal Pharmacare For now, whether your treatment is paid for still depends on your province, your plan, and in some cases the specific medication your prescriber chooses.